


































The link between aging and insulin/IGF-1 signaling has 
attracted substantial attention during last years. The 
potential connection was evidenced by an increase in 
incidence of insulin resistance and type 2 diabetes in 
accelerated aging syndromes, on the one side, as well as 
by life span extension due to caloric restriction (CR) in 
rodents, on the other
  [1]. Concomitant reduction in 
plasma insulin and plasma glucose levels, which implies 
increased sensitivity to insulin, emerges as a hallmark 
of increased longevity [2]. Hyperglycemia is an 
important aging factor involved in generation of 
advanced glycosylation endproducts (AGEs) [3,4]. 
There is evidence that hyperinsulinemia favors 
accumulation of oxidized protein by reducing its 
degradation as well as facilitates protein oxidation by 
increasing steady-state level of oxidative stress [3]. 
Untreated diabetics with elevated glucose levels suffer 
many manifestations of accelerated aging, such as 
impaired  wound   healing,  obesity,  cataracts,  vascular  
 
 
































and microvascular damage [5]. It is important to stress 
that hyperinsulinemia is an significant factor not only in 
aging but also in the development of cancer [5,13-18].  
The concept of CR mimetics is now being intensively 
explored [9-12]. CR mimetics involve interventions that 
produce physiological and anti-aging effects similar to 
CR. It was suggested to use biguanide antidiabetics as a 
potential anti-aging treatment [5,13-18].
  The anti-
diabetic drugs, phenformin and buformin, were 
observed to reduce hyperglycemia and produce the 
following effects: improved glucose utilization; reduced 
free fatty acid utilization, gluconeogenesis, serum 
lipids, insulin and IGF-1, and reduced body weight both 
in humans and experimental animals [5,16-19]. The use 
of phenformin in humans has been limited the last two 
decades because of a potential association with lactic 
acidosis. Widely used antidiabetic biguanide, metformin 
(dimethylbiguanide) does not increase risk for lactic 
acidosis or for increased lactate levels in type 2 diabetes 
[20] but has some adverse effects, including renal 
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transgenic female HER-2/neu mice, it was shown that 
metformin slowed down aging and tumor development 
[24,25]. However, in female SHR mice metformin 
significantly increased life span but failed to inhibit 
spontaneous tumorigenesis [26]. Recently it was shown 
that treatment with metformin did not influence life span 
of male F344 rats [27]. To test strain and gender factors 
in present study we evaluated effects of metformin on 
some parameters of aging, life span and spontaneous 




Age-related body weight dynamics  
 
Male 129/Sv mice were heavier than females over the 
life span both in the control and treated with metformin 
groups (Fig. 1). The body weight of mice in both 
control and metformin-treated groups increased with 
age, exceeding at 18 months the body weight of 3-
month-old animals by 27.7% in the control female 
group, and by 30.5 % in the female group treated with 
metformin. The corresponding indices for males were 































both in male and female mice. On the other hand, there 
was no difference in the mean body weight of mice 
exposed and non-exposed to the drug until the age of 22 
months while afterwards a tendency to the decrease of 
body weight was observed in metformin treated group 
(Fig.1).  
 
Age-related dynamics of food and water consumption  
 
Food consumption gradually increased after the age of 
15 months both in female and male mice. The amount 
of food daily consumed by male mice was higher than 
in females throughout the whole period of observation 
(Fig. 2). It was approximately similar in the controls 
and in metformin-treated male and female groups until 
the age of 1 year.  However, at the age of 15 to 21 
months the food consumption was slightly but 
significantly (p<0.05) decreased in metformin-treated 
male group as compared with respective control (Fig.2). 
The amount of water consumed by mice varied during 
the period of observation and was slightly increased by 
10-20% in metformin-treated group practically at all 
ages (Fig. 3). Again (like in case of food consumption), 
males drank more water than females in both control 















































































Age-related dynamics of body temperature  
 
The body temperature was measured only in females. It 
decreased between 6th and 9th month of life and was 
practically at the same level until the age of 24 months.  
Temperature was higher in metformin-treated group 
than that in the controls at the age of 15 month of age 
but was lower than in control group at the age of 24 















































Age-related dynamics of estrous function in mice  
 
The length of estrous cycles in the control and 
metformin-treated female 129/Sv mice was not 
significantly changed with age, whereas it was shorter 
in the group of animals treated with metformin and aged 
6 and 9 months (Table 1). The fraction of mice with 
regular estrous cycles decreased with the age uniformly 



























































































































Rate of estrous cycles of various length 
(%) 
Fraction of mice 
with regular 
cycles (%)  
<5 days  5-7 days  >7 days 
Control 
3  5.8 ± 0.25   24   58  18  83 
6  5.6 ± 0.24  26  61  13  92 
9  6.0 ± 0.24  11  78  11  98 
12  5.3 ± 0.28  36  50  14  94 
15  4.8 ± 0.20  43  51  6  93 
18  5.6 ± 0.25  27  58  15  88 
21  6.1 ± 0.38  18  64  18  75 
24  7.0 ± 0.79  0  78  22  62 
Metformin 
3  5.9 ± 0.22  13  81*  6  93 
6  4.9 ± 0.17*   42  53  5  100  
9  5.3 ± 0.25*   37**   51**  12  95 
12  5.2 ± 0.18  37  59  5  98 
15  5.1 ± 0.28  28  70  2  93 
18  5.5 ± 0.25  12  82*  6  87 
21  5.9 ± 0.45  14  68  18  72 














Control  5.18 ± 0.30  3.44 ± 0.13  1.32 ± 0.07  1.64 ± 0.30 
Metformin  6.14 ± 0.47  3.13 ± 0.12  1.30 ± 0.57  1.35 ± 0.08 
There were 10 animals in each group.  
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and non-treated with metformin 
  
No any difference was revealed in the levels of glucose, 
total cholesterol, triglycerides and insulin between 21-
month-old male mice in control and metformin-treated 
















Age-related dynamics of the chromosome aberration 
































The total incidence of the chromosome aberrations in 
bone marrow of both control and treated mice increased 
with age. As compared with controls the chromosome 
aberrations value was  increased in mice treated with 
metformin at the age 7, 18 and 22 months (p<0.001) 
(Table 3). Of note, this increase was related to the 
increase of incidence of single bridges whereas the 
incidence of multiple bridges was significantly 
decreased in 22-month-old metfromin-treated mice as 
compared with control mice of the same age.   
 
 Survival and longevity of 129/Sv mice 
 
According to the log-rank test [28] the difference in 
survival of both male and female 129/Sv mice exposed 
to metformin treatment, compared to the control group, 
is non-significant (p-value is 0.359 for males and 0.652 
for females). Survival dynamics in control and 
metformin-treated male and female mice are shown in 
Fig. 5, A and C. It is worthy of note that though there is 
no difference in life span distributions between male 
and female controls (p-value is 0.571, χ2=0.3 on 1 df)  
metformin treatment evidently produced somewhat 
different effect on survival of male and female mice, 
since the difference in life span distributions of males 
and females under metformin action became statistically 
significant (p-value is 0.0474, χ


































Age, months  Treatment  Total 
incidence 




bridges, %  
Fragments, 
% 
4  Control  15.4 ± 0.02  8.1 ± 0.01  5.3 ± 0.02  2.0 ± 0.01 
7  Control  19.1 ± 0.01  8.0 ± 0.01  11.1 ± 0.01  0 
Metformin  27.3 ± 0.01*  14.1± 0.02*  12.1 ± 0.01  1.1 ± 0.01 
18  Control  23.0 ± 0.06  7.2 ± 0.02  15.30 ± 0.04  0.5 ± 0.01 
Metformin  28.0 ± 0.05*  15.1±0.02 *  12.50 ± 0.02  0.4 ± 0.01 
22  Control  28.9 ± 0.02  8.5 ± 0.01  18.0 ± 0.02  2.4±0.01 











































In males, metformin treatment significantly decreased 
the mean life span of all mice (-13.4%, p < 0.05) but not 
so in long-living individuals (last 10% of survivors) as 
well as it did not influence maximum life span (Table 
4). In females, the mean life span and median of this 
parameter in metformin-treated animals  were slightly 
increased (+4.4% and 7.8% respectively, p>0.05) in 
comparison to the controls, whereas mean life span of 
last 10% survivors and maximum life span were the 
same as in the control (Table 5). However, it deserves 
mentioning that until the age of 700 days survived 
54.1% of mice in the control female group and 72.9% of 
metformin-treated females (p<0.03; Fischer’s exact 
test). 
 








































as the rate of aging, was lower (by 1.67 times) in the 
male group subjected to metformin treatment than in 
controls males, whereas the mortality rate doubling 
time (MRDT) was increased in metformin-treated 
group of male mice (Table 4).  In females, the 
parameter α was increased by 1.43 times and MRDT 
was decreased as compared to the relevant controls 
(Table 5). 
 
According to the estimated parameters of the Cox’s 
regression model being a female under metformin 
treatment decreases the relative risk of death compared 
to the male group kept under the same treatment. Cox's 
regression model parameters for all mice (males and 
females) was estimated as follows: β = -0.415; exp(β) = 












































Spontaneous tumor development in 129/Sv mice 
 
The dynamics of age-related increase in spontaneous 
tumor development is represented at the Fig. 5, B and 
D. The mean latent period of tumor development was 
similar in male and female mice of both groups (Tables 
4 and 5). According to the long-rank test [28] there 
were no significant differences in age-related 
distributions of the total tumors occurrence in control 
and metformin-treated groups of both sexes.  
 
The first tumor-bearing male mouse died at the age of 
592 days in the metformin-treated group and at the 702 
days in the control male group. Total tumor incidence in 









































death from the first tumor in the experiment) was 
28.0%.and 31.8% in the metfromin-treated animals 
(Table 4).  There were no significant differences in the 
incidence of malignant or benign tumors of any 
localization between the control and metformin-treated 
male mice.  
 
In the female mice, the total tumor incidence was 
similar in the control and metformin-treated groups. 
However, the incidence of malignant tumors was 
significantly decreased (by 3.5 times) in the group given 
metformin in comparison to the control (Table 5). 
Benign vascular tumors of the uterus and ovary 
developed most frequently in female 129/Sv mice 
(Table 5), in line with oncological characteristics of this 
Table 4. Effect of metformin on life span and tumorigenesis in male 129/Sv mice 
 
Parameters  Control Metformin 
Number of mice  41 46 
Effective number of mice 
25 22 
Mean life span, days (М±S.E.M.)  662±30.0 573±33.7*  (-13.4%) 
Mediana, days  680 586 
Mean life span of last 10% survivors, days  951±32.5 931±28.7 
Maximum life span, days  1029 1044 
α×10
-3 , days
-1  5.19 (4.37; 6.27)  3.10 (2.42; 3.48)* 
MRDT, days  134 (111; 159)  224 (199; 287)* 
Number of tumor-bearing mice (%)  7 (28.0%)  7 (31.8%) 
Number of malignant tumor-bearing mice (%)  5 (20.0%)  5 (22.7%) 
Mean life span of tumor-bearing mice, days  835±45.2  804±62.1 
Total number of tumors  11  8 
Number of malignant tumors   6  5 
Localization and type of tumors 
Skin:                                            carcinoma  1  - 
Liver:                                     haemangioma     





 Lung:                                            adenoma 





Spleen:                                          leukemia  -  1 
 Colon:                                                polyp 





Prepucial gland:                      cystadenoma  2  - 
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metformin-exposed animals. Thus, in toto uterine and 
ovarian haemangiomas and haemangioendoteliomas 
were revealed respectively in 54.2% of control and 
68.8% of metformin-exposed female mice, p < 0,03 
(Fisher’s exact test). At the same time the differences in 
the incidence of angiogenic tumors only of ovaries or 
utery between treated and untreated with metformin was 
not statistically significant. 
 
There was no significant difference in the incidence of any 










































In this paper for the first time were shown gender 
differences in effect of metformin on survival, life span 
and spontaneous carcinogenesis in 129/Sv mice. The 
reasons for these differences are at present unclear. 
There are several possibilities explaining these 
observations. One of them could be fundamental 
differences in mechanism of aging in males and 
females, another – gender peculiarities in the targets of 
drugs, including metformin. This question needs a 














































Parameters  Control Metformin 
Number of mice  48 48 
Effective number of mice 
48 48 
Mean life span, days (М±S.E.M.) 
711± 24.3  742 ± 15.8 (+4.4%) 
Median, days  715 771  (+7.8%) 
Mean life span of last 10% survivors, days 
910 ± 8.9  913 ± 19.2 
Maximum life span, days  945 966 
α×10
-3 , days
-1  7.27 ( 6.36; 8.20)  10.40 (8.90;12.50)* 
MRDT, days  95 (84;109)  67 (56; 78)* 
Number of tumor-bearing mice (%)  31 (64.6%)  34 (70.8%) 
Number of malignant tumor-bearing mice (%)  7 (15.6%)  2 (4.2%)* 
Mean life span of tumor-bearing mice, days  766 ± 27.3  764 ± 18.4 
Total number of tumors  46  50 
Number of malignant tumors   9  2* 
Localization and type of tumors 
Uterus:  haemangioma &  haemangioendotelioma 
                                                   adenocarcinoma 







Ovary:                                 granulesa-cell tumor 
           haemangioma & haemangioendothelioma 









Lung:                                                     adenoma 





Liver:                           hepatocellular carcinoma  1  - 


































Several years ago, it was originally suggested to use 
antidiabetic biguanides as mimetics of caloric restriction 
(CR) and a potential anti-aging treatment [5].  In a 
number of studies it was shown that treatment with 
biguanides (phenformin, buformin and metformin) 
increased life span and suppressed spontaneous 
tumorigenesis, however, in some experiments it failed 
to modify these parameters (Table 6). The causes of the 
observed contradictions are not completely clear. One 
of them could be differences in a dose of the drug, 
however, it is worthy of note that male and female 
129/Sv mice demonstrated different reaction to the 
same dose of metformin.  Also, it deserves mentioning 
that metformin failed to increase life span of male F344 
rats [27]. 
 
Inhibitor of mammalian target of rapamycin  (mTOR) 
increased life span of female in larger extend than in 
male hybrid mice [33].  It is worthy to note, the mean 
life span extension was observed in female (+20.4%) 
but it was not increased in male S6K1
-/-  mice [34]. 
Deletion  of ribosomal S6 protein kinase 1 (S6K1), a 
component of the nutrient-responsive mTOR  signaling 
pathway, led to increased life span in mice and to 
resistance to age-related pathologies, such as bone, 





























motor dysfunction and loss of insulin sensitivity [34]. 
Deletion of S6K1 induced gene expression patterns 
similar to those seen in CR or with pharmacological 
activation of adenosine monophosphate (AMP)-
activated protein kinase (AMPK), a conserved regulator 
of the metabolic response to CR. The mean life span of 
oldest 10% survivors and maximum life span were also 
increased only in females. There was no difference in 
the incidence of macroscopic tumors in S6K1
-/- and wild 
type mice.   
 
Comparison of effects of metformin on various 
biomarkers of aging in different strains of mice shows 
rather notable similarity in observed patterns (Table 7). 
Thus, the body weight and food consumption were 
unchanged or slightly decreased at some periods of life 
in metformin-treated rodents.  The body temperature 
was similar in control and metformin-treated mice. In 
females of 3 strains (129/Sv, HER-2/neu and SHR), the 
slow down of age-related disturbances in estrous 
function have been observed. It is worthy of note that in 
women with polycystic ovary syndrome metformin 
improves menstrual regularity, leading to spontaneous 
ovulation, and enhances the induction of ovulation with 
clomiphene citrate [35]. 
Table 6. Effect of antidiabetic drugs on life span and spontaneous carcinogenesis in rodents 
 












Mice C3H/Sn  F  Phenformin +21.8% +26.0%  ↓ [13] 
FVB/N
a F  Metformin  +8.0%  +16.2%  ↓ [24] 
FVB/N
a F  Metformin  +6.7%  -19.3%  ↓ [25] 
SHR F  Metformin  +37.9%  +10.3%  =  [26] 
NMRI F Diabenol  +6.7% +1.4%  ↓ [30] 
FVB/N
a F  Diabenol  0  +6.0%  =  [30] 
HD
b M  Metformin  +20.1%  +18.5%  N.D.
d [31] 
HD
b F  Metformin  0  0  N.D.
d [31] 
129/Sv F  Metformin  +4.4%  +7.8%  ↓ malignant.  
↑ benign 
Present paper 
129/Sv M Metformin  -13.4% +1.5%  =  Present  paper 
Rat LIO  F  Phenformin  0  9.8%  ↓ [15] 
LIO F  Buformin +7.3%  +5.5%  ↓ [15] 




































Treatment with metformin failed influence metabolic 
parameters in male 129/Sv mice and was followed by 
some improvements in female SHR and HER-2/neu 
mice. Metformin inhibited tumorigenesis in female 
129/Sv and HER-2/neu mice and did not affect it in 
male 129/Sv and female SHR mice. In female 129/Sv 
mice treatment with metformin inhibited development 
of malignant tumors and increased the total incidence of 
benign angiogenic tumors. These data are in according 
with observations that metformin can to increase VEGF 
expression, intratumoral microvascular density and 
reduced necrosis thus promote the angiogenic 
phenotype and increased tumorigenic progression [36]. 
 
The incidence of chromosome aberrations in male 
129/Sv mice was significantly higher at young, middle 
and old age than that in male CBA, SHR, FVB/N, 
C57BL/6J mice of the same age groups [37]. Treatment 
with metformin increased the incidence of chromosome 
aberrations in male 129/Sv mice that was in agreement 
with the observed reduction of life span in males 
exposed to the drug. The comparative study on the 
effect of metformin on female and male F344 rats 
would be important for understanding gender 
differences in response to metformin in rodents.  
 
It is worthy to note, that experiments in yeast and 
C.elegans show that the life extension by CR is not a 
mechanical output of low calories and consequence of a 
reduction in ROS or AGE formation, but a process that 

























respiration that activates the regulator SIR2 [38]. It was 
observed that phenformin inhibits proliferation and 
induced enhanced and transient expression of the cell 
cycle inhibitor p21 and apoptosis in human tumor cells 
lines [39]. 
 
Buformin was supplemented to nutrient medium in 
various concentrations (from 1.0 to 0.00001 mg/ml) 
during the larvae stage and over the life span of C. 
elegans. The drug given at the concentration of 0.1 
mg/ml increased the mean life span of the worms by 
23.4% (p < 0.05) and the maximum life span by 26.1% 
as compared to the controls [40].  Metformin 
supplementation (50 mM dose) was shown to increase 
the mean life span, but not maximum, of C. elegans, 
although 10 or 100 mM doses showed no significant life 
span benefit [41]. The authors have shown that 
metformin prolongs nematode healthspan, slowing 
lipofuscin accumulation, extending mean life span, and 
prolonging youthful locomotor ability in a dose-
dependent manner. Genetic data suggest the metformin 
acts through a mechanism similar to that operative in 
eating-impaired CR mutants, but independent of insulin 
signaling pathway. Energy sensor AMPK and AMPK-
activating kinase LKB1, which are activated in 
mammals by metformin treatment [42,43], are essential 
for health benefits in C. elegans, suggesting that 
metformin engages a metabolic loop conserved across 
phyla. It was also shown that metformin activated SKN-
1/Nrf2, oxidative stress-responsive transcription factor 
[41].   
Table 7. Effect of metformin on biomarkers of aging in rodents of various strains 
 
Strain, species:  129/Sv mice  SHR mice  HER-2 mice  F344 rats 
Sex: M  F  F  F  F  M 
References:  Present paper  [26]  [24]   [25]   [27] 
Body weight  ↓ =  =↓ =  ↓ = 
Food consumption  ↓ =  =  ↓ = = 
Body temperature  ND   ↑ = = =  = 
Estrous function  ↑   ↑  ↑ =  
Tumor 
development 
=  ↓ malignant 
↑ benign 
=  ↓ ND  ND 
Glucose =  ND  =  ↓ = ND 
Triglycerides =  ND  ↓  ↓ ND  ND 
Cholesterol = ND =  =  ND ND 
Insulin =  ND  =  =  =  ND 
Life span   ↓  ↑  ↑  ↑ = = 
Notes: ND ‐ not detected; ↓ ‐ decreased; ↑ ‐ increases; = no effect. 
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anticarcinogens. There are several suggestions on the 
mechanism of anti-carcinogenic and anti-tumor effects 
of metformin. Firstly, metformin is commonly 
considered to function as a sensitizer to insulin [5,43-
46]. The antidiabetics biguanides inhibit fatty acid 
oxidation, suppress gluconeogenesis in the liver, 
increase the availability of insulin receptors, inhibit 
monoamine oxidase [44], increase sensitivity of 
hypothalamo-pituitary complex to negative feedback 
inhibition, reduce excretion of glucocorticoid 
metabolites and dehydroepiandrosterone-sulfate [5]. It 
was shown that metformin decreases platelet superoxide 
anion production in diabetic patients [47].  The capacity 
of metformin to activate AMPK (AMP-activated protein 
kinase) has been suggested to constitute an insulin-
independent mechanism of inhibitory effect of 
metformin on proliferation of cancer cells, directly 
connected with promotion of the inhibition of the 
AMPK down-stream mammalian effector target of 
rapamycin (mTOR) [48-53]. 
 
mTOR controls cell growth and metabolism in response 
to nutrients (e.g., amino acids), insulin and growth 
factors such as IGF-1. Since TOR is activated by 
nutrients and insulin, calorie restriction deactivates 
TOR. Calorie restriction extends life span in a variety of 
species including primates [12,54]. Recently it was 
demonstrated that  rapamycin like metformin extends 
life span in mice [33]  and delays the development of 
mammary carcinomas in HER-2/neu transgenic mice 
[25]. Both rapamycin and biguanides inhibit carcino-
genesis in rodents [25,46,55-59].  
 
Our results alongside with recent findings of mTOR 
signaling pathway involvement in regulation of aging 
[34] and evidence of significant life span extension of 
mammals with rapamycin and calorie restriction [33,54]  
suggest that mimetic of calorie restriction, antidiabetic 
biguanide metformin may be rapidly contemplated for 
pharmacological intervention at a population level.   
 
MATERIALS AND METHODS 
 
Animals. Inbred 129/Sv mice were breed at the animal 
facility of N.N. Petrov Research Institute of Oncology. 
The mice were kept 5-7 in polypropylene cages (30 x 21 
x 10 cm) under standard light/dark regimen (12 hours 
light :12 hours darkness) at 22 ± 2 °C,  and received 
standard laboratory chow [60]  and tap water ad libitum. 
 
Experimental design. Eighty seven male and 96 female 
129/Sv mice at the age of 3 months were randomly 
divided into two groups. Mice of the first group were 
given metformin (1,1- Dimethylbiguanide hydro-
chloride, Biomedicals, France) with drinking water (100 
mg/kg) daily, whereas the mice of the second group 
were given tap water without metformin and served as a 
control. This dose of metformin is similar to used in our 
earlier experiments with transgenic HER-2/neu and 
outbred SHR mice [24-26]
  and equal to 300 mg/m
2 of 
the surface area. Recalculation for humans gives in 
average 510 mg/m
2, that much less than commonly used 
in clinical practice (1.0 – 2.5 g per day). Once a week 
all mice were palpated for detection of tumor mass 
appearance. Once a month all mice were weighted and, 
simultaneously, the amount of consumed food and 
water was measured, and the rate of the consumed water 
(ml) and food (g) per mouse were calculated. Once in 
every 3 months, daily for 2 weeks vaginal smears of the 
animals were cytologically examined to estimate the 
estrous function. In the same period, rectal body 
temperatures of female mice were measured with an 
electronic thermometer, TPEM (KMIZ, Russia). 
 
At the age of 21 month 10 male mice from the control  
group and the group treated with metformin were 
sacrificed by decapitation after overnight starvation. 
Samples of serum were obtained and stored at the -20
oC 
for subsequent analyses. Other animals were observed 
until their natural deaths. The date of each death was 
registered, and the mean life span, the age at which 90% 
of the animals died, and the maximum life span were 
estimated. 
 
Metabolic and hormonal assays.  The serum levels of 
glucose were estimated by enzymocolorimetric 
(glucose-oxidase) method with kits from  “Impact” 
(Moscow, Russia); cholesterol and triglycerides - by 
enzymocolorimetric method with kits of  “Olvex” 
(St.Petersburg, Russia); insulin - by immune enzyme 
assay (ELISA) with kits from Diagnostic Systems 
Laboratories, Inc. (U.S.A.).  
 
Cytogenetic study.  Chromosomal aberrations in bone 
marrow cells was studied by modified  Ford’s method  
described in Rosenfeld et al. [37]. Mice were sacrificed 
with ether anaesthesia. Both femurs of each mouse were 
dissected and bone marrow cells  flushed gently with  
0.56% KCl solution into a centrifuge tube. Cells were 
treated for 20 min with hypotonic solution and fixed 
with ethanol: acetic acid mixture (3:1). Slides were 
stained with 4% acetoorseine. 20-30 well spread 
anaphases were analyzed for each animal and cells with 
chromosome breaks, acentric fragments, and other 
aberrations were evaluated on 1,000X magnification 
with a light microscope (Leitz, Germany). 
 
Pathomorphological examination.  All animals were 
autopsied. Site, number and size of mammary tumors 
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as well as the tissues and organs with suspected tumor 
development were excised and fixed in 10% neutral 
formalin. After the routine histological processing the 
tissues were embedded into paraffin. 5-7 μm thin 
histological sections were stained with haematoxylin 
and eosine and were microscopically examined. Tumors 
were classified according to International Agency for 
Research on Cancer recommendations [61]. 
 
Statistics. Experimental results were statistically 
processed by the methods of variation statistics with the 
use of STATGRAPH statistic program kit. The 
significance of the discrepancies was defined according 
to the Student t-criterion, Fischer exact method, χ
2, non-
parametric Wilcoxon-Mann-Whitney and Friedman RM 
Anova on Ranks. Student-Newman-Keuls method was 
used for all pairwise multiple comparisons. Coefficient 
of correlation was estimated by Spearman method [62]. 
Differences in tumor incidence were evaluated by the 
Mantel-Haenszel log-rank test. 
 
Parameters of Gompertz model were estimated using 
maximum likelihood method, non-linear optimization 
procedure [63] and self-written code in 'Matlab'; 
confidence intervals for the parameters were obtained 
using the bootstrap method [64]. 
 
For experimental group the Cox regression model [65] 
was used to estimate relative risk of death and tumor 
development under the treatment compared to the 
control group: h(t, z) = h0(t) exp(zβ), where h(t,z) and 
h0(t) denote the conditional hazard and baseline hazard 
rates, respectively,  β is the unknown parameter for 
treatment group, and z takes values 0 and 1, being an 
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